Key result
Nifekalant facilitates both depolarization- and hyperpolarization-activated currents in D540K hERG channels, indicating that facilitation is induced by pore opening rather than voltage sensor movement.
Why the study?
Certain hERG blockers facilitate hERG activation to increase currents and potentially reduce proarrhythmic risk, but the underlying molecular mechanism remained unclear.
Nifekalant facilitates hERG channel activation by stabilizing the open conformation of the pore, providing a molecular mechanism for its secondary agonistic effects that may reduce proarrhythmic risk.
Mechanism of hERG facilitation by blockers remains unclear; leaves open proarrhythmic risk assessment in drug development.
A drug that blocks the cardiac myocyte voltage-gated K + channels encoded by the human Ether-à-go-go-Related Gene (hERG) carries a potential risk of long QT syndrome and life-threatening cardiac arrhythmia, including Torsade de Points . Interestingly, certain hERG blockers can also facilitate hERG activation to increase hERG currents, which may reduce proarrhythmic potential. However, the molecular mechanism involved in the facilitation effect of hERG blockers remains unclear. The hallmark feature of the facilitation effect by hERG blockers is that a depolarizing preconditioning pulse shifts voltage-dependence of hERG activation to more negative voltages. Here we utilize a D540K hERG mutant to study the mechanism of the facilitation effect. D540K hERG is activated by not only depolarization but also hyperpolarization. This unusual gating property of the D540K hERG channel enables testing of hypotheses about the mechanism by which voltage induces facilitation of hERG by blockers. With D540K hERG, we find that nifekalant, a hERG blocker and Class III antiarrhythmic agent, facilitates not only current activation by depolarization but also current activation by hyperpolarization. Our results indicate that induction of facilitation is coupled to pore opening, not voltage per se . We propose that a gated-access mechanism is involved in the voltage-dependence of induction of facilitation. This study provides a molecular mechanism for modulation of hERG channels by nifekalant, a clinically important antiarrhythmic agent. Significance statement Nifekalant is a clinically important antiarrhythmic agent and a hERG blocker which can also facilitate voltage-dependent activation of hERG channels after a preconditioning pulse. Here we show that the mechanism of action of the preconditioning pulse is to open a conductance gate to enable drug access to a facilitation site. Moreover, we find that facilitation increases hERG currents by altering pore dynamics, rather than acting through voltage sensors.
No takes yet. Share an insight, caveat, or question.
Furutani et al. (2022) studied hERG channel gating / Long QT syndrome mechanism. Nifekalant vs. Control (no drug) or WT hERG was evaluated on Voltage-dependence of activation (V1/2) shift. Nifekalant facilitates both depolarization- and hyperpolarization-activated currents in D540K hERG channels, indicating that facilitation is induced by pore opening rather than voltage sensor movement.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: